parsaclisib: Clinical Trials

16 trials of parsaclisib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 3 terminated, 2 active not recruiting, 1 unknown. 16 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 216Completed 9, Terminated 3, Active not recruiting 2, Unknown 1, Withdrawn 1
Phase 15Terminated 2, Active not recruiting 1, Completed 1, Unknown 1

Follow parsaclisib: new trials by email Literature Review of parsaclisib trials Research Report on parsaclisib

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL
Parsaclisib, CHOP - PI3Kδ Inhibitor, Parsaclisib
Phase 1 / Phase 2UnknownFudan University302022-03-012022-02-14
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
tafasitamab, parsaclisib - Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Phase 1 / Phase 2TerminatedIncyte Corporation542021-09-162026-02-04
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
tafasitamab, lenalidomide, parsaclisib - Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma
Phase 1 / Phase 2Active not recruitingIncyte Biosciences Japan GK722020-12-152026-10-21
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
parsaclisib - Lymphoma
Phase 2CompletedIncyte Biosciences Japan GK422020-09-302024-10-23
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib - B-Cell Malignancies
Phase 2Active not recruitingIncyte Corporation1122020-08-032026-06-25
IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
IBI376 - Indolent Non-hodgkin Lymphoma
Phase 2CompletedInnovent Biologics (Suzhou) Co. Ltd.812020-04-072024-06-05
A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris
Parsaclisib - Pemphigus Vulgaris
Phase 2WithdrawnIncyte Corporation2019-03-012019-09-13
A Study of INCB050465 in Primary Sjögren's Syndrome
Parsaclisib - Primary Sjögren's Syndrome
Phase 2CompletedIncyte Corporation102019-02-282021-08-13
A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
Parsaclisib - Autoimmune Hemolytic Anemia
Phase 2CompletedIncyte Corporation252018-11-212025-07-11
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
Parsaclisib - Lymphoma
Phase 2CompletedIncyte Corporation1262018-03-142025-03-14
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Parsaclisib - Lymphoma
Phase 2CompletedIncyte Corporation1102017-12-182025-07-11
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
Parsaclisib - Lymphoma
Phase 2CompletedIncyte Corporation1622017-11-202025-03-18
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Parsaclisib - Lymphoma
Phase 2CompletedIncyte Corporation602017-03-022025-08-22
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Parsaclisib, Ruxolitinib - MPN (Myeloproliferative Neoplasms)
Phase 2TerminatedIncyte Corporation742017-02-082024-05-01
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Parsaclisib, Itacitinib, Rituximab - B-Cell Malignancies
Phase 1 / Phase 2CompletedIncyte Corporation882016-09-222023-09-28
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
INCB052793, gemcitabine, nab-paclitaxel - Solid Tumors, Advanced Malignancies
Phase 1 / Phase 2TerminatedIncyte Corporation832014-09-102020-04-17

Conditions studied

Lymphoma, Non-Hodgkin (6)  ·  Lymphoma (5)  ·  Hereditary Sensory and Autonomic Neuropathies (3)  ·  Lymphoma, Follicular (3)  ·  Lymphoma, B-Cell, Marginal Zone (2)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Myeloproliferative Disorders (2)  ·  Recurrence (2)  ·  Anemia, Hemolytic, Autoimmune (1)  ·  Leukemia (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Neoplasm Metastasis (1)  ·  Pemphigus (1)  ·  Primary Myelofibrosis (1)

Sponsors

Incyte Corporation (12)  ·  Incyte Biosciences Japan GK (2)  ·  Fudan University (1)  ·  Innovent Biologics (Suzhou) Co. Ltd. (1)

Countries

United States (11)  ·  Italy (7)  ·  France (6)  ·  Spain (6)  ·  Belgium (5)  ·  Poland (5)  ·  United Kingdom (5)  ·  Czechia (4)  ·  Denmark (4)  ·  Germany (4)  ·  Israel (4)  ·  Australia (3)  ·  Austria (3)  ·  Japan (3)  ·  Canada (2)

Top investigators

Kathleen Butler, MD (3)  ·  Fred Zheng, MD (2)  ·  Albert Assad, MD (1)  ·  Claudia Corrado, M.D. (1)  ·  Claudia Corrado, MD (1)  ·  Ekaterine Asatiani, M.D. (1)  ·  Fred Zheng, MD, PhD (1)  ·  Junning Cao (1)  ·  Oliver Manzke, MD (1)

Results publications

PMID 30803990, PMID 33140664, PMID 38290135, PMID 39435908, PMID 40365847, PMID 41563911

NIH funding

2017 (4), 2016 (1), 2019 (1)